Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy - A randomized, double-blind, placebo-controlled trial
Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy - A randomized, double-blind, placebo-controlled trial
复制标题
DOI：
10.1001/archinte.162.12.1409
复制
发表时间：
2002-06-24
影响因子：
--
通讯作者：
Hildebolt, CF
中科院分区：
文献类型：
--
作者：
Civitelli, R;Pilgram, TK;Hildebolt, CF
背景资料：我们进行了一项为期3年的双盲、随机、安慰剂对照研究，以确定激素/雌激素替代疗法（H/ERT）对颅后骨密度的积极作用是否伴随着对口腔骨量的类似积极作用。共有135名绝经后妇女年龄41-70岁，无中度或重度牙周病的患者随机接受每日口服结合雌激素治疗（倍美力; 0.625 mg）单独或与醋酸甲羟孕酮（分别为Prempro; 0.625和2.5 mg）或安慰剂组合。所有受试者均接受碳酸钙（1000 mg/d）和胆钙化醇（800 IU/d）补充剂。主要疗效终点为牙槽嵴高度和牙槽骨密度的变化。牙槽嵴高度在咬翼片上测量，牙槽骨质量的变化通过数字减影X线摄影进行评估。结果：激素/雌激素替代治疗与安慰剂相比显著增加了牙槽骨质量（+1.84%vs +0.95% [P=.04]），并倾向于改善牙槽嵴高度（+4.83%vs +3.46% [P=.34]）。与安慰剂组相比，H/ERT组股骨近端的骨密度显著增加（股骨近端总骨密度，+3.59% vs +0.22% [P=.00];股骨颈，+2.05% vs -0.34% [P=.02];股骨转子，+3.49% vs +0.08% [P =.05]）。
Background: We conducted a 3-year, double-blind, randomized, placebo-controlled study to determine whether the positive effects of hormone/estrogen replacement therapy (H/ERT) on postcranial bone density are accompanied by similar positive effects on oral bone mass.Methods: A total of 135 postmenopausal women (aged 41-70 years) with no evidence of moderate or severe periodontal disease were randomized to receive daily oral conjugated estrogen (Premarin; 0.625 mg) alone or in combination with medroxyprogesterone acetate (Prempro; 0.625 and 2.5 mg, respectively) or placebo. All subjects received calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/d) supplements. The primary efficacy end points were the changes in alveolar crest height and alveolar bone density. Alveolar crest height was measured on bite-wing radiographs, and changes in alveolar bone mass were assessed by means of digital-subtraction radiography. Postcranial bone density was measured in the lumbar spine and left proximal femur by means of dual-energy x-ray absorptiometry.Results: Hormone/estrogen replacement therapy significantly increased alveolar bone mass compared with placebo (+1.84% vs +0.95% [P=.04]), and tended to improve alveolar crest height (+4.83% vs +3.46% [P=.34]). Bone mineral density of the proximal femur significantly increased in the H/ERT compared with the placebo group (total proximal femur, +3.59% vs +0.22% [P=.00]; neck, +2.05% vs -0.34% [P=.02]; trochanter, +3.49% vs +0.08% [P